NCT06976476View on ClinicalTrials.gov

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

May 8, 2029

Study Completion Date

May 8, 2029

Conditions
Multiple MyelomaHypogammaglobulinemiaHypogammaglobulinemia, Acquired
Interventions
DRUG

IgPro20

Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump

Trial Locations (8)

10029

NOT_YET_RECRUITING

Mount Sinai Hospital, New York

10065

RECRUITING

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER